Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06809595
Active, not recruiting Phase 3

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

NCT06809595 · tracked via the Priya Life Science France tracker
Sponsor
Definium Therapeutics US, Inc
Phase
Phase 3
Started
2025-01-29
Last updated
2026-09-04

Condition(s) studied

Generalized Anxiety Disorder

Investigational drug(s) / intervention(s)

PlaceboDT120 →

Placebo: A substance that is designed to have no therapeutic value

DT120: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Study summary

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

Eligibility

Sex
ALL
Min age
18 Years
Max age
74 Years
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis of GAD per DSM-5 2. Male or female aged 18 to 74 3. HAM-A Total Score ≥20 Exclusion Criteria: 1. Certain psychiatric disorders (other than generalized anxiety disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine) 4. Any clinically significant unstable illness

Primary outcome measure(s)

  • Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 — Baseline to Week 12
    The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Trial sites (36)

FacilityCityRegionStatus
Preferred Research Partners, Inc. Little Rock Arkansas
Psychedelic Science Institute Los Angeles California
West Los Angeles VA Medical Center Los Angeles California
Bradenton Research Center, Inc. Bradenton Florida
Clinical Neuroscience Solutions, Inc Orlando Florida
Atlanta Center for Medical Research Atlanta Georgia
Sheppard Pratt Health System Towson Maryland
Adams Clinical Boston Boston Massachusetts
Princeton Medical Institute Princeton New Jersey
University of Cincinnati Psychiatry- Anxiety Disorders Research Program Cincinnati Ohio
Neuro-Behavioral Clinical Research, Inc. North Canton Ohio
Austin Clinical Trial Partners Austin Texas
Core Clinical Research Everett Washington
A-shine s.r.o. Pilsen Czechia
Institut Neuropsychiatricke Pece (INEP) Prague Czechia
Psyon s.r.o. Prague Czechia
Cabinet Dr.Desbonnet : Résidence Saint Michel Douai France
Hôpital Conception, CIC Centre, bat néphrologie 3eme étage Marseille France
CMME Paris France
GHU Paris Psychiatrie et Neurosciences Paris France
Centre Hospitalier du Rouvray Sotteville-lès-Rouen France
Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin Berlin Germany
OVID Clinic Berlin Berlin Germany
Central Institute of Mental Health Mannheim Germany
Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie Tübingen Germany
Centrum Badan Klinicznych PI-House sp. z o.o. Gdansk Poland
Department of Psychiatry, UCK Gdansk Poland
Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz Lodz Poland
Neuroclin Glasgow Glasgow United Kingdom
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital Gosforth United Kingdom
4 Medical Clinical Solutions London United Kingdom
Clerkenwell Health - Baker Street London United Kingdom
Clerkenwell Health London United Kingdom
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital London United Kingdom
4 Medical Clinical Solutions Manchester United Kingdom
St George's Community Health Centre Sheffield United Kingdom

Other trials for the same condition

Qualitative Study of Student Financial Insecurity and Psychiatry Starting soon
Cohort Study on Medical Students' Mental Health Recruiting
Electroclinical Correlation of Anxiety Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06809595 on ClinicalTrials.gov ↗ ← All trials in France